Literature DB >> 24801111

Penetration force, geometry, and cutting profile of the novel and old Ozurdex needle: the MONO study.

Carsten H Meyer1, Zengping Liu, Christian K Brinkmann, Eduardo B Rodrigues, Thomas Bertelmann.   

Abstract

PURPOSE: To investigate the geometry, penetration force, and cutting profile of the novel and old needle of the drug delivery system (DDS) for Ozurdex injections in a standardized laboratory setting.
METHODS: In this experimental study, the normative geometrical data of the DDS needle were systematically analyzed according to nomenclature DIN 13097 (ISO 7864) and ISO 9626. The force to penetrate a standardized 0.4-mm-thick polyurethane foil was measured by a penetrometer, when the needle was piercing, cutting, and sliding through the foil and plotted as a load-displacement diagram. Magnified images of the consecutive cut were taken after the entire penetration through the foil.
RESULTS: In this experimental study, the mean point length was equal to 3.34 mm (3.28-3.36 mm) for the old DDS needle versus 3.33 mm (3.30-3.36 mm) for the new DDS needle. The secondary bevel length was 1.64 mm (1.42-1.73 mm) for the new and 1.66 mm (1.62-1.69 mm) for the old needle. The primary angle was 9.2° (9.0°-9.5°) for the old and 8.9° (8.5°-9.0°) for the new needle, respectively. The secondary bevel angle was 117.2° (116°-118°) for the old and 111.4° (110°-113°) for the new needle. The mean penetration force of the old DDS needles was significantly higher at all phases of the penetration experiment: The mean piercing force was 0.7 Newton (N) with the old and 0.47 N with the new DDS needle. The mean cutting force was remarkable higher with 1.1 N for the old DDS needle versus 0.78 N for the new DDS needle. The dilatation phase was not statistically significant between 0.94 and 0.99 N in both DDS needles. The friction phase was maintained at significantly higher levels with the old DDS needle of 0.47 N, whereas it returned to the lowest measurements of 0.11 N with the new DDS needle. Both DDS systems induced a characteristic chevron-shaped incision.
CONCLUSION: A comparison of the old and new DDS needles demonstrated a reduced penetration force with the modified new DDS needle, which may help to achieve a smooth penetration through the human sclera.

Entities:  

Mesh:

Year:  2014        PMID: 24801111      PMCID: PMC4043432          DOI: 10.1089/jop.2013.0231

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  18 in total

1.  Prefilled syringe needles versus standard removable needles for intravitreous injection.

Authors:  Igor Kozak; April Dean; Thomas M Clark; Iryna Falkenstein; William R Freeman
Journal:  Retina       Date:  2006 Jul-Aug       Impact factor: 4.256

2.  Intravitreal dexamethasone implant in patients with persistent diabetic macular edema.

Authors:  Ilaria Zucchiatti; Rosangela Lattanzio; Giuseppe Querques; Lea Querques; Claudia Del Turco; Maria Lucia Cascavilla; Francesco Bandello
Journal:  Ophthalmologica       Date:  2012-02-03       Impact factor: 3.250

3.  Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.

Authors:  Wolfgang J Mayer; Matthias Remy; Armin Wolf; Daniel Kook; Anselm Kampik; Michael Ulbig; Lukas Reznicek; Christos Haritoglou
Journal:  Ophthalmologica       Date:  2012-06-23       Impact factor: 3.250

4.  Ocular rigidity in living human eyes.

Authors:  Ioannis G Pallikaris; George D Kymionis; Harilaos S Ginis; George A Kounis; Miltiadis K Tsilimbaris
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-02       Impact factor: 4.799

Review 5.  Diabetic macular edema.

Authors:  Gabriele E Lang
Journal:  Ophthalmologica       Date:  2012-04-24       Impact factor: 3.250

6.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal:  Ophthalmology       Date:  2010-04-24       Impact factor: 12.079

7.  Release and velocity of micronized dexamethasone implants with an intravitreal drug delivery system: kinematic analysis with a high-speed camera.

Authors:  Carsten H Meyer; Adrian Klein; Florian Alten; Zengping Liu; Boris V Stanzel; Hans M Helb; Christian K Brinkmann
Journal:  Retina       Date:  2012 Nov-Dec       Impact factor: 4.256

8.  Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion.

Authors:  Lea Querques; Giuseppe Querques; Rosangela Lattanzio; Silvia Rita Gigante; Claudia Del Turco; Giulia Corradetti; Maria Lucia Cascavilla; Francesco Bandello
Journal:  Ophthalmologica       Date:  2012-09-19       Impact factor: 3.250

9.  Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies.

Authors:  Rahul N Khurana; Suri N Appa; Colin A McCannel; Michael J Elman; Susan E Wittenberg; David J Parks; Saad Ahmad; Steven Yeh
Journal:  Ophthalmology       Date:  2013-07-24       Impact factor: 12.079

10.  [Reliability and safety of intravitreal Ozurdex injections. The ZERO study].

Authors:  K Schmitz; M Maier; C R Clemens; F Höhn; J Wachtlin; F Lehmann; T Bertelmann; K Rüdiger; M Horn; A Bezatis; G Spital; C H Meyer
Journal:  Ophthalmologe       Date:  2014-01       Impact factor: 1.059

View more
  6 in total

Review 1.  Recent advances in intraocular sustained-release drug delivery devices.

Authors:  Yiqi Cao; Karen E Samy; Daniel A Bernards; Tejal A Desai
Journal:  Drug Discov Today       Date:  2019-06-04       Impact factor: 7.851

2.  Scleral tunnel leakage induced by injection of dexamethasone intravitreal implant for recurrent Vogt-Koyanagi-Harada disease: a case report.

Authors:  Ying Huang; Bing Lin; Li-Na Ge; Xiao-Ling Liu
Journal:  Int J Ophthalmol       Date:  2021-12-18       Impact factor: 1.779

Review 3.  Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema.

Authors:  Hemal Mehta; Mark Gillies; Samantha Fraser-Bell
Journal:  Ther Adv Chronic Dis       Date:  2015-09       Impact factor: 5.091

4.  In vitro release of hydrophobic drugs by oleogel rods with biocompatible gelators.

Authors:  Russell Macoon; Mackenzie Robey; Anuj Chauhan
Journal:  Eur J Pharm Sci       Date:  2020-06-12       Impact factor: 4.384

5.  Novel Needle for Intravitreal Drug Delivery: Comparative Study of Needle Tip Aspirates, Injection Stream and Penetration Forces.

Authors:  Lyubomyr M Lytvynchuk; Goran Petrovski; Adien Dam; Joep Hiemstra; Tobias Wimmer; Iryna Savytska; Susanne Binder; Knut Stieger
Journal:  Clin Ophthalmol       Date:  2021-02-19

6.  Iatrogenic subretinal injection of Ozurdex® implant and its effect on macular edema.

Authors:  Smita Shriram Karandikar; George J Manayath; Veerappan Saravanan; Siddharth Narendran; Venkatapathy Narendran
Journal:  Oman J Ophthalmol       Date:  2017 May-Aug
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.